Skip to main content

Table 3 Cox univariate analyses of metastasis-free survival.

From: Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

Region of amplification Population 5-year M FS [95% CI] Hazard ratio [95% CI] p-value
  W hole N + N - With amplification Without amplification   
8p12 +    68.75 [56.73–83.3] 82.4 [76.6–88.7] 2.25 [1.28–3.93] 0.0046
8p12   +   63.2 [46.6–85.6] 72.6 [63–83.67] 1.87 [0.95–3.71] 0.071
8p12    + 73.77 [57.59–94.49] 91.33 [85.37–97.70] 2.98 [1.1–8.06] 0.031
8q24 +    78.6 [59.8–100] 82.61 [77.63–87.92] 0.825 [0.25–2.75] 0.75
8q24   +   75 [50.3–100] 74.53 [66.32–83.75] 0.728 [0.17–3.04] 0.66
8q24    + 83.3 [58.3–100] 89.55 [84.09–95.36] 0.825 [0.09–7.66] 0.87
11q13 +    75.93 [65.28–88.31] 83.95 [79.18–89] 1.46 [0.8–2.67] 0.22
11q13   +   75.72 [61.54–93.17] 74 [65.7–83.4] 0.962 [0.44–2.1] 0.92
11q13    + 76.02 [60.88–94.92] 91.72 [86.91–96.80] 2.46 [0.93–6.48] 0.069
12p13 +    91.67 [77.29–100] 82.23 [77.85–86.85] 0.427 [0.06–3.08] 0.4
12p13   +   100 [100-100] 72.14 [64.84–80.26] * 1
12p13    + 83.3 [58.3–100] 91.28 [86.85–95.94] 2.46 [0.32–18.75] 0.39
17q12 +    64.7 [47.5–88.2] 83.92 [79.28–88.83] 2.09 [1.02–4.26] 0.044
17q12   +   68.2 [48.6–95.7] 75.37 [67.54–84.10] 1.24 [0.52–2.95] 0.63
17q12    + 55.6 [27.4–100] 91.25 [86.44–96.33] 4.2 [1.18–14.95] 0.027
20q13Z +    85.4 [71.27–100] 79.43 [73.82–85.47] 0.57 [0.18–1.83] 0.35
20q13Z   +   90.91 [75.41–100] 63.98 [54.65–74.89] 0.186 [0.03–1.35] 0.097
20q13Z    + 79.5 [57.7–100] 93.05 [88.18–98.19] 2.58 [0.55–12.15] 0.23
20q13Co +    90.43 [78.63–100] 79.80 [74.71–85.24] 0.364 [0.09–1.51] 0.16
20q13Co   +   87.84 [73.37–100] 66.80 [58.20–76.66] 0.276 [0.07–1.15] 0.076
20q13Co    + 100 [100-100] 90.40 [85.35–95.75] * 1
  1. *No event in the amplified group